VIVUS Inc. (VVUS)

4.01
0.03 0.74
NASDAQ : Health Technology
Prev Close 4.04
Open 4.07
Day Low/High 3.96 / 4.09
52 Wk Low/High 2.15 / 5.78
Volume 13.76K
Avg Volume 113.90K
Exchange NASDAQ
Shares Outstanding 10.64M
Market Cap 41.61M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
VVUS February 14th Options Begin Trading

VVUS February 14th Options Begin Trading

Investors in Vivus, Inc. saw new options begin trading today, for the February 14th expiration.

February 7th Options Now Available For Vivus (VVUS)

February 7th Options Now Available For Vivus (VVUS)

Investors in Vivus, Inc. saw new options become available today, for the February 7th expiration.

Vivus is Now Oversold (VVUS)

Vivus is Now Oversold (VVUS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Interesting VVUS Put And Call Options For January 31st

Interesting VVUS Put And Call Options For January 31st

Investors in Vivus, Inc. saw new options begin trading today, for the January 31st expiration.

VVUS January 24th Options Begin Trading

VVUS January 24th Options Begin Trading

Investors in Vivus, Inc. saw new options begin trading today, for the January 24th expiration.

VIVUS Collaborates With Aetna To Test First Comprehensive Weight Management Program Integrating Weight Loss Medication

VIVUS Collaborates With Aetna To Test First Comprehensive Weight Management Program Integrating Weight Loss Medication

New Program, Available Now, Integrates Qsymia to Help Bridge the Gap Between Lifestyle Interventions and Surgical Treatments

January 10th Options Now Available For Vivus (VVUS)

January 10th Options Now Available For Vivus (VVUS)

Investors in Vivus, Inc. saw new options become available today, for the January 10th expiration.

The Billion-Dollar Biotech Club: Speculation Trumped Risk

The Billion-Dollar Biotech Club: Speculation Trumped Risk

The list of biotech and drug stocks with billion-dollar market values almost doubled in 2013 -- a sign that investors loved speculation and were rewarded for it.

Looking at What Didn't Work

Looking at What Didn't Work

Time to examine a couple that didn't pan out.

Interesting VVUS Put And Call Options For December 27th

Interesting VVUS Put And Call Options For December 27th

Investors in Vivus, Inc. saw new options begin trading today, for the December 27th expiration.

Vivus (VVUS) Showing Signs Of Perilous Reversal Today

Vivus (VVUS) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Vivus (VVUS) as a "perilous reversal" (up big yesterday but down big today) candidate

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look poised to trade higher from current levels.

Biotech Stock Mailbag: Enteromedics, ARCA Biopharma, Keryx Pharma

Biotech Stock Mailbag: Enteromedics, ARCA Biopharma, Keryx Pharma

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

[video] A Chart You Should See: Investors Put Greater Weight Behind Orexigen Than Arena, Vivus

[video] A Chart You Should See: Investors Put Greater Weight Behind Orexigen Than Arena, Vivus

Orexigen Therapeutics is the best-performing obesity drug stock of 2013, topping rivals Vivus and Arena Pharma.

[video] Orexigen Weight-Loss Pill Passes Safety Hurdle

[video] Orexigen Weight-Loss Pill Passes Safety Hurdle

Contrave will be resubmitted for FDA approval "within a few weeks," Orexigen said.

VIVUS Announces Support For New Obesity Treatment Guidance Urging Active Involvement From Healthcare Providers

VIVUS Announces Support For New Obesity Treatment Guidance Urging Active Involvement From Healthcare Providers

New Guidelines and Publication Encourage Physicians and Patients to Work Together to Find the Right Treatment Plan, Which May Include Medication

Kyle Bass Gets In On Herbalife, Microsoft, J.C. Penney

Kyle Bass Gets In On Herbalife, Microsoft, J.C. Penney

Kyle Bass’ Hayman Capital got in on a few embattled and controversial stocks during the September quarter. His latest 13F filing shows that his new stocks for the September quarter included Herb...

November 22nd Options Now Available For Vivus (VVUS)

November 22nd Options Now Available For Vivus (VVUS)

Investors in Vivus, Inc. saw new options become available today, for the November 22nd expiration.

5 Stocks With Big Insider Buying

5 Stocks With Big Insider Buying

Insiders at these companies have been scooping up shares of their own stock lately.

Insider Trading Alert - MOS, VVUS, XRAY, PSX And IVZ Traded By Insiders

Insider Trading Alert - MOS, VVUS, XRAY, PSX And IVZ Traded By Insiders

Stocks with insider trader activity include MOS, VVUS, XRAY, PSX and IVZ

Top Insider Trades: AGCO VVUS INWK ACRX

Top Insider Trades: AGCO VVUS INWK ACRX

The top 10 open-market insider purchases and sales filed at the SEC Tuesday.

Arena Expands Marketing Of Obesity Drug To Help Shrink Waistlines

Arena Expands Marketing Of Obesity Drug To Help Shrink Waistlines

Chris Lau, Kapitall: ArenaA and a partner will expand marketing efforts for a weight loss drug, but is there more room [...]

Jim Cramer's 6 Stocks in 60 Seconds: VVUS CVS BWLD HAIN PXD ECANE (Update 1)

Jim Cramer's 6 Stocks in 60 Seconds: VVUS CVS BWLD HAIN PXD ECANE (Update 1)

Cramer says to be careful with Vivus but he sees CVS going higher.

TheStreet Quant Rating: D (Sell)